Skip to main content
. 2020 Apr 27;12(5):1087. doi: 10.3390/cancers12051087

Figure 4.

Figure 4

Synergistic inhibition of MDA-MB-468 cell viability by lapatinib and GSK690693. (A) The individual responses of MDA-MB-468 cells to lapatinib and GSK690693 are compared to the response of MDA-MB-468 cells to the combination of both drugs at equal molar concentrations; (B) synergistic dose reduction of lapatinib and GSK690693 on MDA-MB-468 cells as a function of the percentage of viability inhibition. The results are representative of two independent experiments of triplicates.